These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36548906)

  • 21. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
    Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
    Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview.
    Suh SH; Kim SW
    Diabetes Metab J; 2023 Sep; 47(5):612-629. PubMed ID: 37482655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The lipid story in chronic kidney disease: a long story with a happy end?
    Kujawa-Szewieczek A; Więcek A; Piecha G
    Int Urol Nephrol; 2013 Oct; 45(5):1273-87. PubMed ID: 23054316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
    Ahmed MH; Khalil AA
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ongoing challenges for pharmacotherapy for dyslipidemia.
    Pisaniello AD; Scherer DJ; Kataoka Y; Nicholls SJ
    Expert Opin Pharmacother; 2015 Feb; 16(3):347-56. PubMed ID: 25476544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
    Mancini GBJ; Gupta M; Tsigoulis M; Cannon CP; Genest J; Ray KK; Santos RD; Watts GF; Raggi P
    Atherosclerosis; 2017 Aug; 263():112-118. PubMed ID: 28623740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins in chronic kidney disease: what do meta-analyses tell us?
    Upadhyay A
    Clin Exp Nephrol; 2014 Apr; 18(2):278-81. PubMed ID: 24158229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.
    Page MM; Watts GF
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):299-312. PubMed ID: 25861882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCSK9 in chronic kidney disease.
    Pavlakou P; Liberopoulos E; Dounousi E; Elisaf M
    Int Urol Nephrol; 2017 Jun; 49(6):1015-1024. PubMed ID: 28084558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania.
    Vlad CE; Foia L; Pavel-Tanasa M; Toma V; Florea L; Voroneanu L; Apetrii M; Dodi G; Covic A
    Int Urol Nephrol; 2022 Mar; 54(3):647-659. PubMed ID: 34224064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statin use in patients with diabetes and kidney disease: the Japanese experience.
    Koya D; Campese VM
    J Atheroscler Thromb; 2013; 20(5):407-24. PubMed ID: 23518468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.
    Jabarpour M; Rashtchizadeh N; Argani H; Ghorbanihaghjo A; Ranjbarzadhag M; Sanajou D; Panah F; Alirezaei A
    Int Urol Nephrol; 2019 Dec; 51(12):2235-2242. PubMed ID: 31641998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
    Kim K; Ginsberg HN; Choi SH
    Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid-lowering therapy: Guidelines to precision medicine.
    Su X; Cheng Y; Chang D
    Clin Chim Acta; 2021 Mar; 514():66-73. PubMed ID: 33359059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
    Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
    Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 39. [Chronic kidney disease and dyslipidaemia].
    Pascual V; Serrano A; Pedro-Botet J; Ascaso J; Barrios V; Millán J; Pintó X; Cases A
    Clin Investig Arterioscler; 2017; 29(1):22-35. PubMed ID: 27863896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Trends in Dyslipidemia Treatment.
    Jang AY; Lim S; Jo SH; Han SH; Koh KK
    Circ J; 2021 May; 85(6):759-768. PubMed ID: 33177309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.